Cost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States

Abstract

Background In the EMPEROR‐Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction), empagliflozin plus standard of care reduced the composite of cardiovascular death or hospitalization for heart failure versus standard of care in adults with heart failure with reduced ejection fraction. This analysis investigated the cost‐effectiveness of the 2 regimens from the perspective of US payors. Methods and Results A Markov cohort model was developed based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score quartiles and death. Transition probabilities between health states, risk of cardiovascular/all‐cause death, hospitalization for heart failure and adverse events, treatment discontinuation, and health utilities were estimated from trial data. Medicare and commercial payment rates were combined for treatment acquisition, acute event management, and disease management. An annual discount rate of 3% was used. Empagliflozin plus standard of care yielded 18% fewer hospitalizations for heart failure and 6% fewer deaths versus standard of care over a lifetime, providing cost‐offsets while adding 0.19 life years and 0.19 quality‐adjusted life years at an incremental cost of $16 815/patient. The incremental cost‐effectiveness ratio was $87 725/quality‐adjusted life years gained. Results were consistent across payors, subpopulations, and in deterministic sensitivity analyses. In probabilistic sensitivity analyses, empagliflozin plus standard of care was cost‐effective in 3%, 62%, and 80% of iterations at thresholds of $50 000, $100 000, and $150 000/quality‐adjusted life years. Conclusions Empagliflozin plus standard of care may prevent hospitalizations for heart failure, extend life, and increase quality‐adjusted life years for patients with heart failure with reduced ejection fraction at an acceptable cost for US payors.

Keywords

• cost‐effectiveness
• empagliflozin
• heart failure
• sodium–glucose co‐transporter 2 inhibitor
• United States